Undervalued Hashish Shares About to Bounce? | @SC_FUNDS

Midas letter

Undervalued cannabis stocks before the rebound? | @SC_FUNDS

Play episode

Pause episode

Mute / unmute episode

Rewind 10 seconds

1x

Fast forward 30 seconds

00:00
/

Subscribe Share

As from our interview background, we all know that the cannabis sector was underwater for most of 2021. This is because the cannabis stock industry has been plagued by a lack of legislative action, problems with custodians, and now heavy tax losses.

With many winners from other sectors from a solid year in broad markets, investors use cannabis to cash in on their losses. The downtrend is likely to continue until the end of these sales.

However, cannabis stocks may be ready to move higher again. With the events of 2021, many cannabis stocks are valued cheaply as they have made strides in expanding into new states, opening new pharmacies, and achieving great financial performance.

“The underlying US MSO businesses have continued to strengthen, continue to gain access to capital, and continue to grow. And their stock prices have fallen. They were much more attractive in several ways than at the beginning of the year and a year ago. That will obviously affect some investors and you will find some money flowing into it. And with luck, we’ll talk more about law on the way to the US midterm elections next November. and we’ll see stock prices rise in anticipation. ”- Bruce Campbell, Portfolio Manager, StoneCastle Cannabis Growth Fund

Potential catalysts are coming online next year (the biggest of these is the US after Malta in legalizing cannabis). So 2022 could be the year of weed populations again.

Transcript

00:00 – StoneCastle Cannabis Growth Fund Portfolio Manager Bruce Campbell
01:01 – Malta legalization
01:46 – 2022 Outlook for the cannabis industry
04:09 – Reaction of the share price to possible changes in the law
06:36 – CSE step system
07:14 – Biden administration
08:18 – Favorite weed stocks
9:00 am – cannabis stock scandals

Related articles

Disclosure

Midas Letter is provided as a source of information only and should not be construed as investment advice in any way. James West, the author and editor of the Midas Letter, has no authority to advise investors and is only making this information available to readers who are interested in what he invests in and how he makes such decisions.

Investing in emerging publicly traded companies is associated with high risk and investors in such companies could lose all of their money. Before making any investment decision, always consult a properly accredited investment professional in your jurisdiction.

Midas Letter occasionally accepts advertising and sponsorship fees from publicly traded companies listed on this site. James West and / or Midas Letter may also receive compensation from companies associated with the companies featured on this website. James West and / or Midas Letter also invests in companies on this site and therefore readers should view any information on this site as biased.